Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,409 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01048320 | Gemcitabine and Oxaliplatin (Gem-Ox) Plus Glivec in Gemcitabine-refractory Pancreatic Cancer(RPGOG1) | completed | Phase 1 | 36 | Royal Marsden NHS Foundation TrustOTHER | 1 | Sep 25, 2012 | clinicaltrials |
| NCT00006357 | STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma | completed | Phase 1 / Phase 2 | 91 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 |
| Sep 24, 2012 |
| clinicaltrials |
| NCT00677105 | A Safety and Dose-finding Study of JNJ-26481585 for Patients With Advanced Solid Malignancies and Lymphoma. | completed | Phase 1 | 92 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 1 | Sep 17, 2012 | clinicaltrials |
| NCT00920595 | Study of CEP-9722 as Single-Agent Therapy and as Combination Therapy With Temozolomide in Patients With Advanced Solid Tumors | completed | Phase 1 | 26 | CephalonINDUSTRY | 2 | Aug 16, 2012 | clinicaltrials |
| NCT00612209 | A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors(ARQ 197) | completed | Phase 1 | 51 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 1 | Jul 23, 2012 | clinicaltrials |
| NCT00005061 | Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Solid Tumors | completed | Phase 1 | 20 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 3 | Jul 18, 2012 | clinicaltrials |
| NCT00788333 | Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer | completed | Phase 1 / Phase 2 | 40 | Bristol-Myers SquibbINDUSTRY | 5 | Jul 13, 2012 | clinicaltrials |
| NCT00003976 | E7070 in Treating Patients With Solid Tumors | completed | Phase 1 | 30 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Jul 11, 2012 | clinicaltrials |
| NCT00003979 | CHS 828 in Treating Patients With Solid Tumors | withdrawn | Phase 1 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Jul 11, 2012 | clinicaltrials |
| NCT00003980 | BIBX 1382 in Treating Patients With Solid Tumors | suspended | Phase 1 | 80 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Jul 11, 2012 | clinicaltrials |
| NCT00003981 | E7070 in Treating Patients With Solid Tumors | completed | Phase 1 | 30 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Jul 11, 2012 | clinicaltrials |
| NCT00003982 | MEN-10755 in Treating Patients With Solid Tumors | completed | Phase 1 | 30 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Jul 11, 2012 | clinicaltrials |
| NCT00003985 | KRN7000 in Treating Patients With Solid Tumors | withdrawn | Phase 1 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Jul 11, 2012 | clinicaltrials |
| NCT00731263 | A Study of Tor Kinase Inhibitor in Advanced Tumors | completed | Phase 1 | 64 | AstraZenecaINDUSTRY | 3 | Jul 11, 2012 | clinicaltrials |
| NCT00002904 | Ecteinascidin 743 in Treating Adults With Advanced Solid Tumors | completed | Phase 1 | 40 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 14 | Jul 2, 2012 | clinicaltrials |
| NCT00003028 | MEN-10755 in Treating Adults With Recurrent or Refractory Solid Tumors | completed | Phase 1 | 5 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 14 | Jul 2, 2012 | clinicaltrials |
| NCT00076024 | AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 174 | PfizerINDUSTRY | 8 | Jun 26, 2012 | clinicaltrials |
| NCT01147029 | GSAO in Treating Patients With Advanced Solid Tumors That Have Not Responded to Therapy | terminated | Phase 1 | 35 | Cancer Research UKOTHER | 1 | May 1, 2012 | clinicaltrials |
| NCT00989105 | Technetium Tc 99m Demobesin-4 for Imaging Procedures in Patients With Prostate Cancer | terminated | Phase 1 | 8 | Cancer Research UKOTHER | 1 | Feb 28, 2012 | clinicaltrials |
| NCT01147991 | Vaccine Therapy in Treating Patients With Epstein-Barr Virus-Related Cancer | completed | Phase 1 | 16 | Cancer Research UKOTHER | 1 | Feb 28, 2012 | clinicaltrials |
| NCT01212887 | Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer | terminated | Phase 1 | 14 | Cancer Research UKOTHER | 1 | Feb 28, 2012 | clinicaltrials |
| NCT00608907 | An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib) | completed | Phase 1 | 61 | Millennium Pharmaceuticals, Inc.INDUSTRY | 5 | Jan 30, 2012 | clinicaltrials |
| NCT01313390 | Everolimus and Docetaxel in Treating Patients With Recurrent, Locally Advanced, or Metastatic Head and Neck Cancer(DORA) | terminated | Phase 1 / Phase 2 | 4 | University College, LondonOTHER | 1 | Dec 12, 2011 | clinicaltrials |
| NCT00697879 | Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours | completed | Phase 1 | 40 | Chroma TherapeuticsINDUSTRY | 2 | Nov 28, 2011 | clinicaltrials |
| NCT01242943 | Radioimmunotherapy With 131I-L19SIP in Patients With Cancer | terminated | Phase 1 / Phase 2 | 34 | Philogen S.p.A.INDUSTRY | 2 | Nov 22, 2011 | clinicaltrials |
| NCT00395434 | Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors | completed | Phase 1 | 20 | Mateon TherapeuticsINDUSTRY | 1 | Oct 31, 2011 | clinicaltrials |
| NCT00977210 | Safety Study of OXi4503 (a Vascular Disrupting Agent) Given by 3 x Weekly Intravenous Infusions to Patients With Advanced Solid Tumors | completed | Phase 1 | 40 | Mateon TherapeuticsINDUSTRY | 1 | Oct 31, 2011 | clinicaltrials |
| NCT00513851 | Phase 1 Study of OSI-930 in Cancer Patients | completed | Phase 1 | 60 | Astellas Pharma IncINDUSTRY | 2 | Sep 27, 2011 | clinicaltrials |
| NCT00603356 | Phase I Study of OSI-930 and Erlotinib in Cancer Tumors | completed | Phase 1 | 60 | Astellas Pharma IncINDUSTRY | 2 | Sep 27, 2011 | clinicaltrials |
| NCT00748891 | DCE CT/MRI Scanning Study in Patients With Solid Tumours (AstraZeneca and Royal Marsden Hospital Imaging Study) | completed | Phase 1 | 35 | AstraZenecaINDUSTRY | 1 | Jul 1, 2011 | clinicaltrials |
| NCT00099606 | Phase I (PH I) Mad Refractory Solid Tumor Study | completed | Phase 1 | 60 | Bristol-Myers SquibbINDUSTRY | 2 | Apr 19, 2011 | clinicaltrials |
| NCT00285103 | SPC2996 in Chronic Lymphocytic Leukaemia | completed | Phase 1 / Phase 2 | 46 | Santaris Pharma A/SINDUSTRY | 4 | Feb 2, 2011 | clinicaltrials |
| NCT00255489 | A Phase I Study of ZD1839 and Palliative Thoracic Radiotherapy in Patients With Non-small-cell Lung Cancer | completed | Phase 1 | 36 | AstraZenecaINDUSTRY | 1 | Jan 25, 2011 | clinicaltrials |
| NCT00354562 | A Phase 2 Study Evaluating ABT-751 in Combination With Taxotere in Advanced Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 75 | AbbottINDUSTRY | 4 | Jan 7, 2011 | clinicaltrials |
| NCT01270906 | Safety of CHIR-258 (TKI258) in Advanced Solid Tumors | terminated | Phase 1 | 35 | Novartis PharmaceuticalsINDUSTRY | 1 | Jan 5, 2011 | clinicaltrials |
| NCT00516438 | Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan | completed | Phase 1 | 48 | AstraZenecaINDUSTRY | 1 | Dec 8, 2010 | clinicaltrials |
| NCT00689000 | Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM) | completed | Phase 1 / Phase 2 | 57 | Chroma TherapeuticsINDUSTRY | 1 | Oct 22, 2010 | clinicaltrials |
| NCT01019161 | An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML) | completed | Phase 1 | 5 | AstraZenecaINDUSTRY | 1 | Oct 20, 2010 | clinicaltrials |
| NCT00496028 | Phase I Study in Patients With Solid Tumours | completed | Phase 1 | 148 | AstraZenecaINDUSTRY | 4 | Sep 22, 2010 | clinicaltrials |
| NCT00503204 | Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour | completed | Phase 1 | 20 | AstraZenecaINDUSTRY | 2 | Nov 25, 2009 | clinicaltrials |
| NCT00996255 | Dose-Escalation Study of PHA-793887 in Patients With Advanced/Metastatic Solid Tumors | terminated | Phase 1 | 19 | Nerviano Medical SciencesINDUSTRY | 2 | Oct 16, 2009 | clinicaltrials |
| NCT00625768 | Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma | completed | Phase 1 | 13 | Antisoma ResearchINDUSTRY | 2 | Aug 25, 2009 | clinicaltrials |
| NCT00345189 | Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors | completed | Phase 1 | 70 | BiogenINDUSTRY | 2 | Jul 14, 2009 | clinicaltrials |
| NCT00288925 | Z-360 in Unresectable Advanced Pancreatic Cancer in Combination With Gemcitabine Treatment | completed | Phase 1 / Phase 2 | 30 | Zeria PharmaceuticalINDUSTRY | 1 | Jun 1, 2009 | clinicaltrials |
| NCT00516802 | A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine | completed | Phase 1 | 40 | AstraZenecaINDUSTRY | 2 | May 15, 2009 | clinicaltrials |
| NCT00497679 | AZD1152 in Patients With Advanced Solid Malignancies-Study 3 | terminated | Phase 1 | 45 | AstraZenecaINDUSTRY | 1 | May 14, 2009 | clinicaltrials |
| NCT00503412 | Phase I Orally Administered 14C-AZD2171 in Patients With Solid Metastatic Tumors | completed | Phase 1 | 6 | AstraZenecaINDUSTRY | 1 | Jan 19, 2009 | clinicaltrials |
| NCT00633269 | Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic Tumours | completed | Phase 1 | 6 | AstraZenecaINDUSTRY | 1 | Jan 14, 2009 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials